Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

NCT00193557 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]